| Target Price | $615.06 |
| Price | $546.77 |
| Potential | 12.49% |
| Number of Estimates | 32 |
| 32 Analysts have issued a price target Intuitive Surgical 2026 . The average Intuitive Surgical target price is $615.06. This is 12.49% higher than the current stock price. The highest price target is $735.00 34.43% , the lowest is $444.40 18.72% . | |
| A rating was issued by 41 analysts: 27 Analysts recommend Intuitive Surgical to buy, 13 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Intuitive Surgical stock has an average upside potential 2026 of 12.49% . Most analysts recommend the Intuitive Surgical stock at Purchase. |
38 Analysts have issued a sales forecast Intuitive Surgical 2025 . The average Intuitive Surgical sales estimate is $10.1b . This is 5.12% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $10.6b 10.16% , the lowest is $9.5b 0.91% .
This results in the following potential growth metrics:
| 2024 | $8.4b | 17.24% |
|---|---|---|
| 2025 | $10.1b | 20.98% |
| 2026 | $11.6b | 15.11% |
| 2027 | $13.2b | 13.46% |
| 2028 | $14.7b | 11.31% |
| 2029 | $16.1b | 9.88% |
| 2030 | $18.1b | 12.26% |
| 2031 | $18.5b | 1.99% |
| 2032 | $20.1b | 8.57% |
29 Analysts have issued an Intuitive Surgical EBITDA forecast 2025. The average Intuitive Surgical EBITDA estimate is $4.1b . This is 20.52% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $4.6b 32.83% , the lowest is $3.8b 10.68% .
This results in the following potential growth metrics and future EBITDA Margins:
| 2024 | $2.4b | 32.27% |
|---|---|---|
| 2025 | $4.1b | 75.49% |
| 2026 | $4.7b | 13.43% |
| 2027 | $5.6b | 19.06% |
| 2028 | $6.6b | 18.08% |
| 2029 | $7.5b | 13.62% |
| 2030 | $9.2b | 22.25% |
| 2024 | 28.25% | 12.82% |
|---|---|---|
| 2025 | 40.97% | 45.05% |
| 2026 | 40.37% | 1.46% |
| 2027 | 42.37% | 4.95% |
| 2028 | 44.95% | 6.09% |
| 2029 | 46.47% | 3.38% |
| 2030 | 50.61% | 8.91% |
38 Intuitive Surgical Analysts have issued a net profit forecast 2025. The average Intuitive Surgical net profit estimate is $3.2b . This is 14.72% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $3.3b 19.90% , the lowest is $2.9b 4.11% .
This results in the following potential growth metrics and future Net Margins:
| 2024 | $2.3b | 29.18% |
|---|---|---|
| 2025 | $3.2b | 35.68% |
| 2026 | $3.5b | 12.53% |
| 2027 | $4.1b | 15.20% |
| 2028 | $4.7b | 14.98% |
| 2029 | $5.4b | 14.84% |
| 2030 | $6.3b | 17.16% |
| 2031 | $6.7b | 5.64% |
| 2032 | $7.1b | 6.96% |
| 2024 | 27.81% | 10.18% |
|---|---|---|
| 2025 | 31.19% | 12.16% |
| 2026 | 30.49% | 2.24% |
| 2027 | 30.96% | 1.54% |
| 2028 | 31.98% | 3.29% |
| 2029 | 33.42% | 4.50% |
| 2030 | 34.88% | 4.37% |
| 2031 | 36.13% | 3.58% |
| 2032 | 35.60% | 1.47% |
38 Analysts have issued a Intuitive Surgical forecast for earnings per share. The average Intuitive Surgical EPS is $8.79 . This is 15.81% higher than earnings per share in the financial year 2024. The highest EPS forecast is $9.19 21.08% , the lowest is $7.98 5.14% .
This results in the following potential growth metrics and future valuations:
| 2024 | $6.42 | 27.63% |
|---|---|---|
| 2025 | $8.79 | 36.92% |
| 2026 | $9.89 | 12.51% |
| 2027 | $11.40 | 15.27% |
| 2028 | $13.10 | 14.91% |
| 2029 | $15.05 | 14.89% |
| 2030 | $17.63 | 17.14% |
| 2031 | $18.63 | 5.67% |
| 2032 | $19.92 | 6.92% |
| Current | 72.04 | 15.62% |
|---|---|---|
| 2025 | 62.20 | 13.66% |
| 2026 | 55.27 | 11.14% |
| 2027 | 47.98 | 13.19% |
| 2028 | 41.73 | 13.03% |
| 2029 | 36.33 | 12.94% |
| 2030 | 31.01 | 14.64% |
| 2031 | 29.36 | 5.32% |
| 2032 | 27.45 | 6.51% |
Based on analysts' sales estimates for 2025, the Intuitive Surgical stock is valued at an EV/Sales of 18.35 and an P/S ratio of 19.18 .
This results in the following potential growth metrics and future valuations:
| Current | 19.29 | 17.32% |
|---|---|---|
| 2025 | 18.35 | 4.88% |
| 2026 | 15.94 | 13.13% |
| 2027 | 14.05 | 11.87% |
| 2028 | 12.62 | 10.16% |
| 2029 | 11.49 | 8.99% |
| 2030 | 10.23 | 10.92% |
| 2031 | 10.03 | 1.95% |
| 2032 | 9.24 | 7.89% |
| Current | 20.17 | 15.58% |
|---|---|---|
| 2025 | 19.18 | 4.87% |
| 2026 | 16.66 | 13.13% |
| 2027 | 14.69 | 11.87% |
| 2028 | 13.20 | 10.16% |
| 2029 | 12.01 | 8.99% |
| 2030 | 10.70 | 10.92% |
| 2031 | 10.49 | 1.95% |
| 2032 | 9.66 | 7.89% |
Intuitive Surgical...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| UBS |
Neutral
➜
Neutral
|
Unchanged | Oct 23 2025 |
| Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Oct 22 2025 |
| Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Oct 22 2025 |
| Raymond James |
Outperform
➜
Outperform
|
Unchanged | Oct 22 2025 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Oct 22 2025 |
| Truist Securities |
Buy
➜
Buy
|
Unchanged | Oct 22 2025 |
| BTIG |
Buy
➜
Buy
|
Unchanged | Oct 22 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Oct 23 2025 |
|
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Oct 22 2025 |
|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Oct 22 2025 |
|
Unchanged
Raymond James:
Outperform
➜
Outperform
|
Oct 22 2025 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Oct 22 2025 |
|
Unchanged
Truist Securities:
Buy
➜
Buy
|
Oct 22 2025 |
|
Unchanged
BTIG:
Buy
➜
Buy
|
Oct 22 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


